.Pharmacolibrary.Drugs.ATC.C.C02CC04

Information

Debrisoquine is a sympatholytic antihypertensive agent formerly used for the treatment of hypertension. It is recognized mostly for its use as a probe drug for CYP2D6 pharmacogenetic phenotyping. As of now, debrisoquine is rarely used clinically.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult volunteers after oral administration.

References

1. Sjöqvist, F, & Bertilsson, L (1984). Clinical pharmacology of antidepressant drugs: pharmacogenetics. Advances in biochemical psychopharmacology 39 359–372. PUBMED:https://pubmed.ncbi.nlm.nih.gov/6380229

2. Mahgoub, A, et al., & Smith, RL (1977). Polymorphic hydroxylation of Debrisoquine in man. Lancet (London, England) 2(8038) 584–586. DOI:10.1016/s0140-6736(77)91430-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/71400

3. Boriani, G, et al., & Magnani, B (1990). [Determination of oxidative phenotype in a sample population and correlation with the pharmacokinetics of propafenone]. Cardiologia (Rome, Italy) 35(2) 163–169. PUBMED:https://pubmed.ncbi.nlm.nih.gov/2208201

Revisions

• 06/2025 initial generated model